The future has arrived #CUBETechFair

CUBE10 - 12 May 2017, Berlin, Germany.
Startups are setting up, speakers are tweaking their talks, and CUBE Tech Fair is ready for you... The inaugural CUBE Tech Fair kicks off tomorrow, and what a show they have for you. CUBE Tech Fair has brought the Crème de la Crème of the tech world to Berlin.

Over 300 startups from our ecosystem will be exhibiting, in addition to pitching for a €1 million prize in CUBE Challenge. The final round will be judged by Apple Co-Founder, Steve Wozniak.

Let's welcome keynote speeches by:

  • Pablos Holman (Founder of Intellectual Ventures Laboratory, notorious hacker)
  • Michael Müller (Mayor of Berlin)
  • Steve Wozniak (Co-Founder of Apple),
  • Robin Wright (Award-winning actress, tech activist),
  • Brigitte Zypries (Federal Minister of Economic Affairs and Energy)

The fireside chats, keynotes speeches, and panel discussions will deep-dive into specific industry areas. Topics include:

  • Infrastructure & Interconnectivity
  • Digital Health & Life Sciences
  • Machinery & Manufacturing
  • Cybersecurity & Hacking
  • Climate Change & Smart Energy Systems
  • Blockchain Innovations and more!

The Welcome Reception has filled up fast, and organisers already have exceptional guests including top startups, corporates and investors - and for good reason. Come, network and enjoy food tech at it's best - CUBE will be serving up bites from the incredible German Michelin-starred chef Christian Lohse. And on top of that all the ingredients are being provided by anti-food-waste startup SirPlus.

Don't have a booked seat? No problem! The event is still open to all Tech Fair badge holders!

On Thursday night, organisers take to the CityCube's terrace for the official Tech Fair party - they will of course be bringing Berlin's party spirit to the tech world.

Still don't have a ticket?! Get one now!

World Pharma News readers can benefit from an exclusive discount - get 30% off the ticket price using our unique promo code worldpharmanewsCUBE17 when you register online here.

About CUBE
CUBE is a Berlin-based global innovation ecosystem that aims to promote, create and foster partnerships between industry players and startups in life sciences & digital health, machinery & manufacturing as well as infrastructure & connectivity. Being part of the CUBE ecosystem allows all participants to collaborate on innovative products and ideas in response to concrete industry needs.

The annual CUBE Tech Fair, our flagship event, will take place for the first time in May 2017. For further information, please visit http://tech-fair.cube-global.com.

Most Popular Now

Therapy using dual immune system cells effectively…

A newly developed immunotherapy that simultaneously uses modified immune-fighting cells to home in on and attack two antigens, or foreign substances, on cancer cells was ...

How to develop new drugs based on merged datasets

Polymorphs are molecules that have different molecular packing arrangements despite identical chemical compositions. In a recent paper, researchers at GlaxoSmithKline (GS...

New drug combination effective against SARS-CoV-2 …

More countries with greater resources are opening up for a more normal life. But COVID-19 and the SARS-CoV-2 virus are still a significant threat in large parts of the wo...

Cleveland Clinic study suggests steroid nasal spra…

A recent Cleveland Clinic study found that patients who regularly use steroid nasal sprays are less likely to develop severe COVID-19-related disease, including a 20 to 2...

Sanofi to focus its COVID-19 development efforts o…

Recent positive interim results of Sanofi's mRNA-based COVID-19 vaccine candidate Phase 1/2 study confirm the company's platform robust capabilities and strategy in mRNA...

Discovery of mechanics of drug targets for COVID-1…

A team of international researchers, including McGill Professor Stéphane Laporte, have discovered the working mechanism of potential drug targets for various diseases suc...

Phase II/III trial shows Ronapreve™ (casirivimab a…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive data from the phase II/III 2066 study, investigating Ronapreve™ (casirivimab and imdevimab) in patients hospit...

Pfizer and BioNTech receive first U.S. FDA Emergen…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use a booster dose of the P...

AZD7442 request for Emergency Use Authorization fo…

AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) com...

Pfizer and BioNTech receive CHMP positive opinion …

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the Europea...

Boehringer Ingelheim acquires Abexxa Biologics to …

Boehringer Ingelheim announced the acquisition of Abexxa Biologics Inc., a biopharmaceutical company taking a new approach in the fields of immuno-oncology and oncology r...

GSK welcomes WHO recommendation for broad roll-out…

GlaxoSmithKline (GSK) plc welcomes and applauds the WHO recommendation for the broader deployment of GSK's RTS,S malaria vaccine to reduce childhood illness and deaths fr...